AU2010217120B2 - Methods for identifying immunobinders of cell-surface antigens - Google Patents

Methods for identifying immunobinders of cell-surface antigens Download PDF

Info

Publication number
AU2010217120B2
AU2010217120B2 AU2010217120A AU2010217120A AU2010217120B2 AU 2010217120 B2 AU2010217120 B2 AU 2010217120B2 AU 2010217120 A AU2010217120 A AU 2010217120A AU 2010217120 A AU2010217120 A AU 2010217120A AU 2010217120 B2 AU2010217120 B2 AU 2010217120B2
Authority
AU
Australia
Prior art keywords
cells
antigen
cell
immunobinder
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010217120A
Other languages
English (en)
Other versions
AU2010217120A1 (en
Inventor
Valerie Hulmann-Cottier
David Urech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010217120(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CH2009/000222 external-priority patent/WO2009155726A2/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010217120A1 publication Critical patent/AU2010217120A1/en
Priority to AU2013203478A priority Critical patent/AU2013203478B2/en
Application granted granted Critical
Publication of AU2010217120B2 publication Critical patent/AU2010217120B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010217120A 2009-02-24 2010-02-22 Methods for identifying immunobinders of cell-surface antigens Active AU2010217120B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203478A AU2013203478B2 (en) 2009-02-24 2013-04-10 Methods for identifying immunobinders of cell-surface antigens

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15510509P 2009-02-24 2009-02-24
US15504109P 2009-02-24 2009-02-24
US61/155,105 2009-02-24
US61/155,041 2009-02-24
CH8322009 2009-06-02
CH832/09 2009-06-02
AUPCT/CH2009/000222 2009-06-25
PCT/CH2009/000222 WO2009155726A2 (en) 2008-06-25 2009-06-25 Humanization of rabbit antibodies using a universal antibody framework
PCT/CH2010/000044 WO2010096941A1 (en) 2009-02-24 2010-02-22 Methods for identifying immunobinders of cell-surface antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203478A Division AU2013203478B2 (en) 2009-02-24 2013-04-10 Methods for identifying immunobinders of cell-surface antigens

Publications (2)

Publication Number Publication Date
AU2010217120A1 AU2010217120A1 (en) 2010-09-02
AU2010217120B2 true AU2010217120B2 (en) 2014-11-20

Family

ID=42631310

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010217120A Active AU2010217120B2 (en) 2009-02-24 2010-02-22 Methods for identifying immunobinders of cell-surface antigens

Country Status (10)

Country Link
US (7) US8227199B2 (enExample)
EP (2) EP3181583A1 (enExample)
JP (1) JP5764071B2 (enExample)
KR (1) KR101595808B1 (enExample)
CN (1) CN102239181A (enExample)
AU (1) AU2010217120B2 (enExample)
CA (1) CA2744103C (enExample)
IL (1) IL212738A (enExample)
MX (1) MX2011007049A (enExample)
WO (1) WO2010096941A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345395B (es) * 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US9329180B2 (en) * 2010-07-19 2016-05-03 Kaohsiung Medical University Preparation of anti-PEG antibody expressing cell and application thereof
TWI386645B (zh) * 2010-07-19 2013-02-21 Univ Kaohsiung Medical 可定量任何聚乙二醇分子與其修飾物之抗聚乙二醇表現細胞
ES2723775T3 (es) 2010-11-08 2019-09-02 Ablynx Nv Polipéptidos que se unen a CXCR2
US8748587B2 (en) 2011-06-02 2014-06-10 Novartis Ag Molecules and methods for modulating TMEM16A activities
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US9045546B2 (en) 2012-05-31 2015-06-02 Novartis Ag Molecules and methods for modulating TMEM16A activities
EP3014271B1 (en) 2013-06-28 2020-03-18 X-Body, Inc. Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
CN105793705A (zh) * 2013-09-30 2016-07-20 X博迪公司 抗原受体的筛选测试
CN111413298A (zh) * 2020-05-27 2020-07-14 深圳市天安至远传感科技有限公司 一种光纤表面等离子体共振传感器、制备方法及检测系统
WO2022120215A1 (en) * 2020-12-03 2022-06-09 The Johns Hopkins University Nanobodies with specific affinity for voltage gated sodium channels
WO2025257154A1 (en) 2024-06-10 2025-12-18 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Flow cytometry method for determining physically interacting cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20030036092A1 (en) * 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5675063A (en) * 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
AU7171098A (en) * 1997-05-01 1998-11-24 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US6060272A (en) * 1997-05-07 2000-05-09 Human Genome Sciences, Inc. Human G-protein coupled receptors
FR2777007B1 (fr) * 1998-04-01 2000-05-26 Orstom Mutants de glycoproteines d'enveloppes de retrovirus et leurs applications biologiques
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6905668B1 (en) 1998-09-25 2005-06-14 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
DE19852800C1 (de) * 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
AU768515B2 (en) * 1999-01-13 2003-12-18 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Use of antibodies for anticancer vaccination
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
CN105175535A (zh) 2002-05-22 2015-12-23 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US20040067496A1 (en) * 2002-10-07 2004-04-08 Robert Pytela System for production and screening of monoclonal antibodies
US20070122852A1 (en) 2002-11-13 2007-05-31 Micromet Ag Method for identifying antigen specific b cells
JP4603894B2 (ja) * 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
JP4336812B2 (ja) * 2003-03-07 2009-09-30 博夫 岩田 細胞に発現する表面抗原を迅速に同定するための分析方法
DE10314412A1 (de) * 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
CN1787798A (zh) 2003-05-13 2006-06-14 日清奥利友集团株式会社 油性化妆品
EP1623229A2 (en) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
CA2533830A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
JP2004107355A (ja) 2003-10-20 2004-04-08 Kokyu Alcohol Kogyo Co Ltd 油性固形化粧料
CN100451012C (zh) 2003-11-20 2009-01-14 三菱瓦斯化学株式会社 液态环己烷-三羧酸酐
CA2560074A1 (en) * 2004-03-18 2005-11-03 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
AU2006220709B2 (en) * 2005-03-04 2012-09-06 Biogen Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CA2655511C (en) * 2005-07-01 2017-03-21 John Schrader Methods of isolating cells and generating monoclonal antibodies
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
EP1918302A3 (en) 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
NZ573557A (en) * 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
CN101675074B (zh) * 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
JP2010222255A (ja) * 2007-06-18 2010-10-07 Mitsubishi Tanabe Pharma Corp 抗体のスクリーニング方法およびそれにより得られる抗体
JP5022818B2 (ja) 2007-08-10 2012-09-12 株式会社 資生堂 毛髪化粧料
MX345395B (es) 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
KR101737466B1 (ko) 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
JP5926896B2 (ja) 2010-09-17 2016-05-25 株式会社 資生堂 唇用固形化粧料

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels

Also Published As

Publication number Publication date
US8227199B2 (en) 2012-07-24
US20100216170A1 (en) 2010-08-26
EP2321354B2 (en) 2019-11-20
AU2010217120A1 (en) 2010-09-02
WO2010096941A1 (en) 2010-09-02
IL212738A0 (en) 2011-07-31
MX2011007049A (es) 2011-08-03
JP5764071B2 (ja) 2015-08-12
EP3181583A1 (en) 2017-06-21
US20180142028A1 (en) 2018-05-24
US9908940B2 (en) 2018-03-06
US20190382498A1 (en) 2019-12-19
EP2321354A1 (en) 2011-05-18
EP2321354B1 (en) 2016-12-07
KR101595808B1 (ko) 2016-02-19
CN102239181A (zh) 2011-11-09
JP2012518390A (ja) 2012-08-16
IL212738A (en) 2015-04-30
US9221905B2 (en) 2015-12-29
CA2744103A1 (en) 2010-09-02
CA2744103C (en) 2018-01-02
KR20110136783A (ko) 2011-12-21
US20130090456A1 (en) 2013-04-11
US20160152716A1 (en) 2016-06-02
US20150024432A1 (en) 2015-01-22
US8465937B2 (en) 2013-06-18
US20120288878A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
AU2010217120B2 (en) Methods for identifying immunobinders of cell-surface antigens
AU2018204035B2 (en) Methods for identifying immunobinders of cell-surface antigens
JP6604989B2 (ja) 細胞表面抗原のイムノバインダーを同定するための方法
AU2013203478B2 (en) Methods for identifying immunobinders of cell-surface antigens
HK1240238A (en) Methods for identifying immunobinders of antigens
HK1240238A1 (en) Methods for identifying immunobinders of antigens
HK1151040B (en) Methods for identifying immunobinders of cell-surface antigens
HK1151040A (en) Methods for identifying immunobinders of cell-surface antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC